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Abstract
Cardiovascular diseases (CVD) are one of the leading causes of death worldwide. Testosterone (T) is an important sex hormone
that triggers several genomic and non-genomic pathways, leading to improvements of several cardiovascular risk factors and
quality of life in men. At the vascular level, the key effect of T is the vasorelaxation. This review discusses the molecular
pathways and clinical implications of T in the vascular system. Firstly, the mechanisms involved in the T vasodilator effect will be
presented. Then, it will be discussed the association of T with the main risks for CVD, namely metabolic syndrome, type 2
diabetesmellitus, obesity, atherosclerosis, dyslipidaemia and hypertension. Several studies have shown a correlation between low
T levels and an increased prevalence of several CVD. These observations suggest that T has beneficial effects on the cardiovas-
cular system and that testosterone replacement therapy may become a therapeutic reality for some of these disorders.
Keywords Androgens . Vasorelaxation . Risk factors .
Cardiovascular diseases . Metabolic syndrome . Diabetes
mellitus . Obesity . Atherosclerosis . Dyslipidaemia . Blood
pressure
Introduction
The predominant endogenous androgen in the bloodstream is
testosterone (T) [1]. Circulating T is mainly bound to serum
proteins, such as sexual hormone-binding globulin (SHBG)
and albumin [2] being the T concentrations higher than its
solubility. Only 2–3% of all circulating T is free [1], reaching
its maximum in 30-year-old men, and continuously decreas-
ing 1–2% per year afterwards [3, 4]. From the molecular point
of view, T can be converted to dihydrotestosterone (DHT) by
the 5α-reductase enzyme or to oestradiol by aromatase [5].
DHT has more affinity for the androgen receptor (AR), being
the most active androgen. Nevertheless, the plasma DHTcon-
centration is much lower compared to T [6] since the adult
male testes produce more T than DHT. However, these levels
can vary with the circadian rhythm and stress. Moreover, T is
not a male-exclusive hormone. Women produce androgens in
the ovaries and adrenal glands [3, 7] and, during the pregnan-
cy, the fetoplacental unit synthesizes androgens and
oestrogens that play an important biological role in these de-
velopment stages [8]. The chemical structure of T can be seen
in Fig. 1.
T presents genomic and non-genomic actions at the vascu-
lar level, and both effects may overlap. The key T effect at the
vascular level is the vasorelaxation, a non-genomic action
(rapid effect) [9]. Over the years, several studies have agreed
that T is an important sex hormone that triggers genomic and
non-genomic pathways, leading to improvements of several
cardiovascular risk factors and quality of life in men [10]. So,
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it is very important to understand the relationship between the
risk factors for cardiovascular diseases (CVD) and T, based on
the knowledge of T vasodilator mechanisms. Thus, in the first
topic of this paper, the mechanisms involved in the T vasodi-
lator effect will be briefly presented and then, in the subse-
quent sections, it will be discussed the association of T with
the main risks for the CVD, namely metabolic syndrome, type
2 diabetes mellitus, obesity, atherosclerosis, dyslipidaemia,
and hypertension. The final aim of this review is to clarify
the clinical implications of testosterone in the vascular system.
Genomic and Non-genomic Overlapping
Vasodilatory Mechanisms of Testosterone
As previous described, at the vascular level, T presents geno-
mic and non-genomic overlapping actions that lead to an im-
provement of the risk factors for the CVD development/
progression [10].
The genomic effects of androgens, including those of T, are
initiated by their passage through the cellular plasma mem-
brane into the cytoplasm. Then, they dissociate from the chap-
erone proteins and bind to AR, leading to alterations in spe-
cific genes. These alterations include an increase of the hydro-
gen sulphide (H2S) production, and consequently vasodilation
via transient receptor potential vanilloid 4 (TRPV4) and large-
conductance Ca2+-activated K+ channels (BKCa) [10].
However, there are only a few studies regarding the androgen
genomic effects at the cardiovascular level. In animal arteries,
it has been suggested that androgens lead to an increase in the
expression of calcium and potassium channels [11, 12] as well
as that of soluble guanylate cyclase [13]. Moreover, an in-
crease in the expression of voltage-dependent calcium chan-
nels in rat heart [14] and T-type calcium currents in neonatal
rat heart [2] by androgens have also been reported. Regarding
the human arteries, it has been shown that androgens cause
another gene alteration that modifies the vascular tone, by
downregulation of L-type voltage-operated Ca2+ channels
(L-type VOCC) and upregulation of β1 subunit of BKCa
channels [15].
As previously mentioned, the main non-genomic effect of
T on the vasculature is the vasorelaxation [9]. The major
mechanisms involved in this effect include the nuclear or
membrane receptor activation, influence of vascular endothe-
lium and activation or blocking of ion channels. Concerning
the activation of androgen nuclear receptors, the participation
of AR in vasodilation is controversial, as some authors sug-
gested the presence of this receptor on the cell membrane [16].
Moreover, some authors observed that the T vasodilatory ef-
fect was inhibited by the AR antagonist [17, 18]. On the other
hand, several authors demonstrated that the use of the AR
antagonist (flutamide) [19–21], albumin-bound androgen an-
alogues, which cannot pass through the membrane [19] and
protein synthesis inhibitors [22] are not involved in T vasodi-
lator effect. Besides, some authors also observed that T in-
duced vasodilation in arteries without the nuclear functional
AR [20, 23, 24], thereby demonstrating that this effect was not
mediated by AR [20]. Several hypotheses have been proposed
to explain the rapid androgens’ vascular responses, namely a
steroid nuclear receptor translocation to the cell membrane
surface, nonspecific effects of steroids on plasma membrane
fluidity or direct allosteric modification of ion channels de-
pendent of binders and G protein-coupled receptors (GPRCs)
[25]. However, concerning T, only nuclear receptor transloca-
tion to the cell membrane surface has been reported. Recently,
four new membrane AR have been suggested to be responsi-
ble for the non-genomic effects of androgens. Two of them are
GPCR (OXER1 and GPR6A) and the other ion channels/
transporters for calcium and zinc (TRPM8 and ZIP9) respec-
tively [23, 24].
Regarding the vascular endothelium, the key contributor to
the androgen vasorelaxation effect is controversial. Some
studies demonstrated that vascular endothelium has a major
role in the T vasodilator mechanism [26, 27], depending on
species and gender. On the contrary, others demonstrated that
this effect may occur through an independent-endothelium
pathway [28–30], by direct action of Ton the vascular smooth
muscle. This last pathway seems to involve activation of the
receptor coupled to Gi/o protein, activating protein kinase A,
which in turn leads to a hyperpolarization and consequently
small conductance calcium-activated potassium (SKCa) and
BKCa channels activation [31].
Concerning the effects on ion channels, several studies
suggested that T exerts its vasodilatory effects by modulating
different K+ and/or Ca2+ channels [15, 21, 32–34]. The vas-
cular tone is controlled by the ion flow, and the activation of
K+ channels represents the key mechanism involved in the
relaxation [35, 36]. This activation of K+ channels causes a
membrane hyperpolarization that closes the Ca2+ channels,
leading to vasorelaxation [37, 38], and showing the close re-
lationship between the channels mentioned. Most works agree
Fig. 1 Chemical structure of testosterone (T)
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that T activates the K+ channels and/or inhibits the VOCC. In
this case, the authors suggested that Tcan directly inhibit these
channels [30, 39] or that this inhibition can occur indirectly by
the K+ channels activation, mainly the KVand BKCa channels
(due to PKG activation upon intracellular cGMP increase)
[40]. Since there is no consensus regarding the exact mecha-
nism of these T effects, more studies must be performed to
establish if they are direct or due to the activation of a signal-
ling pathway.
The overlap between genomic and non-genomic T actions
makes it difficult to define the broad vascular effects of andro-
gens. Increases in androgen concentrations can induce a rapid
first phase effect followed by a broader, second phase; the
genomic effects can modulate the effects of the first phase.
To our knowledge, there are only two studies that demonstrate
simultaneously both types of effects and this analysis is crucial
to determine the repercussions of conceivably long-lasting
therapy with androgens or a maintained increase in androgen
levels. Er et al. (2007), using rat ventricular myocytes, dem-
onstrated that the genomic T effects on L-type VOCC are
completely antagonized by the non-genomic effects following
T addition [41]. More recently, Saldanha et al. (2013) demon-
strated that the genomic effects of androgens changed the
expression of the BKCa β1-subunit, and the BKCa and KV
channels activities change the non-genomic T action. These
authors also suggested that androgens could be beneficial for
the prevention of hypertension, once androgens have direct
vasodilator effects and the increase of the BKCa channels ex-
pression results in greater involvement of KV channels as me-
diators of vasodilation [15].
The vasodilator mechanism of testosterone, including the
genomic and non-genomic actions, is illustrated in Fig. 2. As
can be seen in the figure, both effects may overlap.
Association of Testosterone with Risk Factors
for CVD
Testosterone was initially considered to be harmful to the car-
diovascular system, as men have a high prevalence of CVD
and cardiovascular morbidity and mortality are over 2-fold
greater in men compared to women [42]. However, several
clinical and epidemiological studies have challenged this idea.
It was observed that men with CVD, type 2 diabetes mellitus
(T2DM), obesity, metabolic syndrome (MeSy) and
dyslipidaemia had low levels of T [43–45]. Also, the preva-
lence of CVD increases in ageing men, when T production
declines. These observations suggest that this hormone has
beneficial effects on the cardiovascular system and that the
testosterone replacement therapy (TRT) may become a thera-
peutic reality for some of these pathologies. However, more
recent studies have shown that TRTmay be associated with an
increased incidence of adverse cardiovascular events, leading
to an intensified controversy regarding the cardiovascular ben-
efits of TRT [46–48]. Thus, in this section, we will address the
association of T with the main risk factors for CVD develop-
ment, namely metabolic syndrome, type 2 diabetes mellitus,
obesity, atherosclerosis, dyslipidaemia, and hypertension. An
abstract illustration of the main risk factors for CVD is repre-
sented in Fig. 3.
Testosterone and Metabolic Syndrome and Type 2
Diabetes Mellitus
The MeSy is a complex combination of risk factors for
CVD and diabetes. These factors include dysglycemia
(i.e. elevated fasting glucose), raised blood pressure,
dyslipidaemia (i.e. elevated triglyceride levels and low
high-density lipoprotein (HDL) cholesterol levels) and
obesity [42, 49]. The molecular mechanisms behind this
complex clinical condition can be explained by the bi-
directional mechanism between hypogonadism and
obesity—a mechanism that involves not only adipocytes
but Leydig cells and hypothalamic hormones responsible
for pituitary-testicular axis control. Also, excessive lep-
tin production (as observed in obesity) may be an ally
of this mechanism, as it disrupts testicular [50]. Patients
with MeSy have twice the risk of developing CVD in
the next 5–10 years than individuals without MeSy and
a 5-fold increased risk for developing T2DM [49]. The
most popular definitions used for MeSy are [49, 51]:
WHO (World Health Organization) 1999:
Presence of insulin resistance or glucose > 6.1 mmol/L
(110 mg/dL), 2 h glucose > 7.8 mmol (140 mg/dL)
(required) along with any two or more of the following:
HDL cholesterol < 0.9 mmol/L (35 mg/dL) in men, <
1.0 mmol/L (40 mg/dL) in women
Triglycerides > 1.7 mmol/L (150 mg/dL)
Waist/hip ratio > 0.9 (men) or > 0.85 (women) or body
mass index (BMI) > 30 kg/m2
Blood pressure > 140/90 mmHg
NCEP (National Cholesterol Education Program) ATP3
2005:
Presence of any three or more of the following:
Blood glucose greater than 5.6 mmol/L (100 mg/dL) or
drug treatment for elevated blood glucose
HDL cholesterol < 1.0 mmol/L (40 mg/dL) in men,
< 1.3 mmol/L (50 mg/dL) in women or drug treatment
for low HDL-C
Blood triglycerides > 1.7 mmol/L (150 mg/dL) or drug
treatment for elevated triglycerides
Waist > 102 cm (men) or > 88 cm (women)
Blood pressure > 130/85 mmHg or drug treatment for
hypertension
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IDF (International Diabetes Federation) 2006:
Waist > 94 cm (men) or > 80 cm (women) along with the
presence of two or more of the following:
Blood glucose greater than 5.6 mmol/L (100 mg/dL) or
diagnosed diabetes
HDL cholesterol < 1.0 mmol/L (40 mg/dL) in men, <
1.3 mmol/L (50 mg/dL) in women or drug treatment for
low HDL-C
Blood triglycerides > 1.7 mmol/L (150 mg/dL) or
drug treatment for elevated triglycerides
Blood pressure > 130/85 mmHg or drug treatment for
hypertension
Note: NCEP and IDF definitions are very similar
except in the waist parameter of 102 vs. 94 cm in
men and 88 vs. 80 cm in women.
Fig. 2 Schematic representation of the overlap vasodilator genomic and
non-genomic mechanisms of androgens. The yellow numbers represent
the genomic actions and the blue numbers represent the non-genomic
actions. (1) Androgens cross the plasma membrane and enter the cyto-
plasm, where it dissociates from chaperone proteins and bind to androgen
receptors (AR). (2) Androgens increase the H2S production and leads to
vasodilation via TRPV4 and BKCa. (3) Androgens upregulate β1 subunit
BKCa. (4) Androgens downregulate L-type VOCC. (5) Androgens acti-
vate the ZIP9 and lead to a cAMP increase. (6) Through binding to
GPRC6A (Giα-activation), androgens lead to a cAMP decrease and
ERK pathway activation. These two mechanisms modulate intracellular
Ca2+ levels and lead to vasodilation through mechanisms still unknown.
(7) Through binding to Giα, androgens are thought to activate particulate
guanil cyclase, by a mechanism that is not yet known. (8) Androgens are
thought to activate protein receptors, leading to a cGMP increase by
particulate guanil cyclase activation. This increase in cGMP levels leads
to PKG activation. Through PKG activation, androgens activate (9) Kv
and (10) BKCa channels and inactivate (11) L-type VOCC channels
through mechanisms still unknown. (12) Via androgen receptors (AR),
it is thought that these sex hormones inhibit particulate guanil cyclase.
Legend: , peptide receptor; , androgens; /green arrows, stimu-
lation; /red arrows, inhibition; ?, unknownmechanism; AR, androgen
receptors; BKCa, large-conductance Ca
2+-activated K+ channels; Ca2+,
calcium; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guano-
sine monophosphate; ERK, extracellular signal-regulated kinase;
GPRC6A, G protein-coupled receptor family C group 6-member A;
H2S, hydrogen sulphide; HSP, heat shock proteins; K
+, potassium; Kv,
voltage-gated K+ channels; L-Type VOCC, L-type voltage-operated Ca2+
channels; PKG, protein kinase G; TRPV4, transient receptor potential
vanilloid 4; ZIP9, Zrt- and Irt-like protein 9
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Although some studies have attempted to clarify the mo-
lecular mechanisms underlying T2DM, these remain unclear.
However, most studies agree that there is insulin resistance,β-
cell dysfunction, and apoptosis, as well as oxidative stress,
mitochondrial dysfunction and inflammation [52].
According to the latest systematic reviews and meta-anal-
ysis, there is clear evidence that low levels of T are associated
with an increased risk for MeSy [50, 53–56] and T2DM [54,
57, 58]. Corona et al. (2011) suggested that MeSy can be
considered as an independent cause associated with male
hypogonadism. Although only a few randomized controlled
trials have been reported, TRTseems to be a reliable treatment
to improve metabolic control, as well as central obesity [53]. It
was also reported that T treatment has beneficial effects on all
MeSy components [59]. The main criterion for the diagnosis
of hypogonadism is the low blood T level in men, which
impairs general physical and mental health status and is diag-
nosed in ~ 2% of elderly men. Total and free T levels of less
than 11 nmol/L and 0.22 nmol/L, respectively, are the mini-
mum criteria for the hypogonadism diagnosis in Europe [42,
60]. In 2013, a review performed by Corona et al. (2013)
about male hypogonadism suggested that TRT was able to
improve central obesity in subjects with MeSy, and
glucometabolic control in patients with MeSy and T2DM.
However, the authors admitted that the number of studies
was too small to draw firm conclusions [54]. Regarding the
two studies performed by Brand’s group, a meta-analysis per-
formed in 2011 suggested a sex-dependent association be-
tween T and MeSy, as the total and free T levels were lower
in men with MeSy and higher in women with MeSy, when
compared to men and women without pathologies. However,
there are no indications for a sex-specific association between
SHBG and MeSy, since, in both men and women, MeSy is
associated with lower SHBG levels [55]. In 2014, Brand et al.
suggested that low total and free T were associated with ab-
dominal obesity, hypertriglyceridemia, hyperglycaemia, low
HDL levels and hypertension [56]. In the same year, Cai
et al. (2014) suggested that, in T2DM hypogonadal men,
TRT could improve glycaemic control and decrease triglycer-
ide levels. However, the authors of this systematic review
concluded that the limited number of participants and the con-
founding factors must be considered when assessing the met-
abolic effects of TRT and its long-term influence on
hypogonadal men with T2DM [61].
Another meta-analysis was performed to study the as-
sociation between T and T2DM. Ding et al. (2006)
showed that high T levels were associated with an elevat-
ed risk of developing T2DM in women and with a lower
risk in men, and higher SHBG levels induced a lower risk
of T2DM in women than in men [58]. Corona et al.
(2011) had suggested that T2DM can be independently
associated with male hypogonadism, although TRT seems
to improve glucometabolic control as well as fat mass in
T2DM subjects [57]. More recently, a cohort study and
meta-analysis with postmenopausal women suggested that
the association of SHBG with T2DM did not change with
the menopause status, whereas the associations between
the endogenous sex hormones and T2DM occurred only
in postmenopausal women. SHBG and total oestradiol are
independent risk factors for the development of T2DM in
women and no association was observed between total or
free T with T2DM [62].
Fig. 3 Abstract illustration of the
main risk factors for
cardiovascular diseases (CVD)
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Moreover, several studies clearly showed that TRT induced
metabolic beneficial effects in MeSy and T2DM patients. The
two meta-analyses performed by Corona et al. in hypogonadal
MeSy patients suggested some benefits of TRT in the reduc-
tion of waist circumference, fasting glucose, and insulin resis-
tance, and in the increase of HDL levels [53, 54]. The reduc-
tion of fasting glucose, glycated haemoglobin (HbA1c), tri-
glyceride and body fat were also suggested in hypogonadism
and T2DM patients submitted to TRT, although total choles-
terol, HDL cholesterol, blood pressure, and body mass index
did not seem to be affected [54, 61]. In contrast, patients with
MeSy and/or T2DM in the absence of classic hypogonadism
did not show these TRT benefits regarding glycaemic control
(assessed by HbA1c) or constitutional symptoms reported by
Ageing Male Symptom score [63].
In summary, most of the mentioned studies showed that
low T levels are associated with an increased risk of MeSy
and T2DM. Recent systematic reviews and meta-analyses
showed that this beneficial effect is more important in MeSy
and T2DM hypogonadal males, and the beneficial effects are
not only associated with fasting glucose, glycated
haemoglobin and cholesterol levels, but also with obesity,
which will be explored in the next section.
Testosterone and Obesity
According to theWHO, overweight and obesity are defined as
abnormal or excessive fat accumulation that presents a risk to
health, in which a person with BMI ≥ 25 kg/m2 is generally
considered overweight, while a BMI ≥ 30 kg/m2 is considered
obese [64]. Obesity is directly or indirectly related to metabol-
ic disorders and the development and progression of T2DM. It
leads to inflammation of adipose tissue with consequent
dysglycemia and insulin resistance, alterations in the lipid me-
tabolism and in the blood pressure, which together may lead to
endothelial dysfunction and atherogenesis [65]. Because obe-
sity has been implicated in the pathophysiology of CVD, it is
important to understand the relationship between obesity and
androgen deficiency, and how it contributes to the several
pathophysiological states of the cardiovascular system [66].
As it is well known, obesity leads to a larger size of adipose
cells (the so-called adipocyte hypertrophy) [67], which is a
determinant factor to this metabolic disorder. These metabolic
changes may lead to a reduction of T. In fact, it was demon-
strated that low levels of this sex hormone are associated with
increased fat mass (mainly central adiposity but also visceral
adiposity [66, 68, 69]), and with the reduction of lean mass, in
men [70]. A bidirectional relationship between T and obesity
supports the hypogonadism-obesity cycle [70], but it is still
unclear whether obesity induces low levels of T or vice versa.
It has been suggested that androgen deficiency is a conse-
quence, and not a cause, of obesity [71]. This seems to agree
with other studies that suggest that obesity promotes a faster
decline of T and SHBG levels with age [66, 67, 72], and that
weight loss increases circulating T levels in obese men
[73–75]. Even if the complete mechanism is not yet defined,
these studies suggest that adipocyte hypertrophy and metabol-
ic changes lead to decreased T levels [67].
In adipose tissue, particularly in visceral fat, T is converted
to 17β-oestradiol by aromatase [68] which is highly expressed
in adipocytes [70]. After this enzymatic conversion,
oestrogens act on the hypothalamic–pituitary–gonadal
(HPG)-axis to inhibit the release of hypothalamic
gonadotropin-releasing hormone (GnRH), which in turn in-
hibits the release of pituitary luteinizing hormone (LH) and
ultimately contributes to a decrease of gonadal T [70]. Low T
levels will lead to lower oestrogen levels from aromatization,
reducing the activated ER and, therefore, increasing the vis-
ceral fat deposition and insulin resistance in men. Thus, T
suppresses visceral fat deposition through its aromatization
to oestradiol, which seems to be inversely related to T levels
and to be dependent on ERα and aromatase [69]. An increase
in visceral fat will increase adipocyte size and aromatase ex-
pression, leading to greater conversion of T to oestrogen,
thereby lowering T levels. Obesity can lead to decreased
levels of T and, in turn, low T levels also contribute to an
increase in adiposity [69, 70]. Furthermore, the adipose tissue
is also an endocrine organ secreting several factors that will
influence the pathogenesis of obesity and hypogonadism. This
process is considered as the hypogonadism-obesity-
adipocytokine cycle [70]. In addition to oestrogens, there are
inflammatory adipocytokines (e.g. tumour necrosis factor-al-
pha, TNFα, and interleukin-6, IL-6) whose hypothalamic in-
hibitory action is the same, leading to the reduction of T levels
[70, 76]. Leptin, a hormone derived from adipose tissue that
regulates body weight and food intake, and that stimulates
GnRH under normal conditions, is increased with increased
adiposity [77]. This may render the hypothalamus resistant to
stimulation (unresponsiveness) and unable to lead to a normal
T production [70]. Leptin interference in androgen production
(via the LH-hCG pathway) [78] is another explanation for the
low T levels. Accordingly, it was recently demonstrated that a
high-fat diet decreases T levels through the suppression of
testicular leptin and Janus kinase/signal transducers and acti-
vators of transcription (JAK-STAT) pathway [79]. The fact
that Leydig cells have insulin receptors and are sensitive to
hyperinsulinemia also indicates another direct point of inter-
action between the production and secretion of this hormone
[76, 80]. It seems clear that an increase in adiposity negatively
affects the T secretion through multiple pathways [81], con-
tributing progressively to CVD.
Taken together, these studies show an inverse relationship
between low T levels and obesity, based on a bidirectional
mechanism [70], where each of the two components potenti-
ates the adverse effects of the other, increasing the risk of
CVD [82]. Theoretically, when multiple changes are
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pathologically linked by bidirectional relationships, a thera-
peutic intervention directed at any of them may lead to an
improvement of all associated conditions [83]. However,
whatever the causality direction, T seems to be the key to this
process. TRT has been shown to be effective and to improve
some obesity components, i.e. decreased visceral and body fat
mass, BMI and waist circumference, and increased lean mass,
thus improving the body composition [69]; TRT also resulted
in cardiometabolic factors improvement [70]. However, the
mechanisms underlying T effects on obesity, or vice versa,
are still not fully understood. Obesity is based on metabolic
homeostasis dysregulation (involving different signalling
pathways) but the way it disrupts the endocrine environment
[84], or the causal relationship with T, have not yet been fully
unveiled and therefore require additional investigations. The
relationship between low T levels, obesity, and CVD is very
complex and multifactorial, remaining, so far, poorly under-
stood [82].
Testosterone and Atherosclerosis
Atherosclerosis is characterized by lipid accumulation and
mononuclear leukocyte infiltration in the tunica intima of ves-
sels. The molecular mechanisms that may be involved in the
development and progression of atherosclerosis include the
low-density lipoproteins (LDL) levels increase. Several con-
ditions, mainly hypertension, smoking, and diabetes, have al-
so been associated to the induction of this pathology. As it
affects the cardiac circulation, it can cause myocardial infarc-
tion or stable angina pectoris. Atherosclerosis may also under-
lie ischaemic stroke and transient cerebral ischaemic attack,
and lead to the formation of aneurysms, including in the aorta
[85]. The onset and progression of arteriosclerosis can be de-
tected by a surrogate carotid marker called intima-media
thickness (IMT). This biomarker is measured by carotid ultra-
sonography and it is used worldwide since it is a simple,
reproducible and non-invasive method [86].
Several cross-sectional and longitudinal studies have
shown an inverse association between T levels and carotid
IMT [87–92]. In a study with 403 men, aged 73–94 years,
Van den Beld et al. (2003) observed that T, estrone, and
insulin-like growth factor I (IGF-I) concentrations were in-
versely correlated with mean IMT, and this association was
stronger in the group without CVD [87]. Fukui et al. (2003)
enrolled 253 men with T2DM, with a mean age of 62 years,
and suggested that free T concentrations were inversely corre-
lated with mean IMT and plaque score. Patients with low
concentrations of free T (< 10 pg/mL) had greater IMT and
plaque score mean than those with higher concentrations of
free T [88]. De Pergola et al. (2003), in a study with 127
glucose-tolerant and obese men, aged 18 to 45 years, showed
that T levels were negatively associated with IMT, regardless
of body fat and other well-known cardiovascular risk factors,
suggesting that T may have a direct anti-atherosclerotic effect.
Furthermore, the authors also observed an inverse association
between T levels and BMI, fat mass, and waist circumference
[90]. In a study of 195 men, aged 73 to 91 years, Muller et al.
(2004) suggested that low free T levels and high oestradiol
levels were inversely related to the thickening of the carotid
IMT and these associations were independent of cardiovascu-
lar risk factors [91]. Makinen et al. (2005), in a study of 239
men (40–70 years), demonstrated an association between T
levels, andropause and carotid IMT, suggesting that men with
andropause symptoms, together with impaired sex hormone
status and increased carotid IMT, might benefit from TRT to
decelerate the progression of atherosclerosis and protect them
from its clinical sequelae (i.e. coronary heart disease, ischemic
stroke, and peripheral vascular disease) [92]. In 2006,
Svartberg et al. (2006) suggested that total the T levels of
1482 men, aged 25–84 years, were significantly inversely
related to the carotid IMT, and this association was indepen-
dent of age, CVD risk factors and lifestyle factors but was not
independent of BMI [89]. In a study of 354 men, aged
65 years, Soisson et al. (2012) showed that low free T com-
bined with high C-reactive protein (CRP) levels were associ-
ated with elevated carotid IMT in elderly men, and this asso-
ciation with carotid IMT was not observed for SHBG nor
oestradiol [93]. Farias et al. (2014), in a study of 115 male
patients, aged younger than 70 years, found a negative corre-
lation between carotid IMT and total T concentration in
middle-aged men with T2DM. Men who had low T levels
also hadmore atherosclerotic plaques, endothelial dysfunction
and higher levels of high-sensitivity CRP [94]. Moreover, Lee
et al. (2014), in a study with 50-year-old men with sexual
dysfunction (308) observed a significant negative correlation
between total T levels and the Framingham Risk Score (FRS)
[95]. This is a scoring system derived from the Framingham
heart study conducted in the United States and is an instru-
ment that uses a simple past medical history and gender-
specific cholesterol levels in asymptomatic patients to predict
the incidence rate of CVD in the next 10 years [96, 97]. In this
sense, Lee et al. (2014) suggested that a higher T level may
decrease the 10-year risk of CVD, and the occurrence of ath-
erosclerosis, coronary artery disease and coronary events [95].
In contrast to these studies, Lee et al. (2016), using a large
cohort of 3164 men from 4 ethnic origins (Caucasian, African
American, Hispanic American and Asian American), aged 45
to 84 years, and without known CVD, observed that lower
free T was associated with a higher relative risk of coronary
artery Ca2+ score > 0 and lower total T was associated with
higher log coronary artery Ca2+ score. Lower total and free T
were associated with lower IMT [98].
In summary, high levels of T seem to have an anti-
atherosclerotic effect, although one study did not observe such
a correlation. This discrepancy needs to be clarified, mainly
considering some CVD risk factors such as diabetes or
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obesity, which also appear to be involved in the progression of
atherosclerosis.
Testosterone and Dyslipidaemia
Dyslipidaemia is one of the main risk factors for CVD [70,
99]. The molecular mechanisms of dyslipidaemia mainly in-
volve an imbalance of the lipid profile, characterized by low
levels of HDL and high levels of LDL [99, 100]. Additionally,
dyslipidaemia may include high levels of total cholesterol,
triglycerides (TG) and very low-density lipoprotein (VLDL)
[70], as well as reduced activity of lipoprotein lipase, a protein
associated with increased risk of coronary artery disease
(CAD) [100].
As previously mentioned, Tcan lead to dyslipidaemia, con-
tributing to the development of CVD. Specifically, low T
levels are an integral part of the MeSy, characterized not only
by dyslipidaemia, but also by obesity, diabetes and hyperten-
sion [101]. Haffner et al. (1993) showed that there is a corre-
lation between low levels of T and high levels of LDL, total
cholesterol and TG, and low levels of HDL [102]. Moreover,
Agledahl et al. (2008) inversely associated the total Twith TG,
and positively with HDL [103]. Following these authors,
Makinen et al. (2008) correlated T directly with HDL and
inversely with total cholesterol and TG [104]. Other authors,
in addition to the positive association of T with HDL [105],
also found an inverse relationship with VLDL levels [105,
106]. TRT was associated with beneficial decreases in LDL,
total cholesterol and TG [70, 107]. Increases in HDL levels
have also been reported after TRT, although there are contra-
dictory studies where a decrease [108, 109] or no change [110]
occurred. An explanation for these differences has not yet
been found, but it is assumed that the T stimulation of reverse
cholesterol transport may lead to increased HDL-C consump-
tion [70].
Overall, individuals with low T levels seem to have a pro-
atherogenic lipoprotein pattern, and thus, a higher propensity
to develop MeSy and CVD. Although multiple factors con-
tribute to atherosclerosis, dyslipidaemia has been considered
as the main cause of this disease [111], with T playing a key
role. In this sense, TRT induces a more favourable lipid pro-
file, contributing to a decrease in CVD occurrence. In sum-
mary, androgens seem to provide a protective effect against
the development and/or progression of atherosclerosis [111,
112].
Testosterone and Blood Pressure
Physiologically, blood pressure can be defined by Ohm’s law,
as being proportional to cardiac output and vascular resistance
to blood flow. However, several other factors, in an integrated
manner, characterize the molecular mechanism of this risk
factor. Specifically, the baroreceptors detect acute pressure
changes in vessels; natriuretic peptides are increased due to
higher pressure on the heart; the renin-angiotensin-
aldosterone system influences vascular tone homeostasis; the
adrenergic system influences heart rate, contraction and vas-
cular tone; and other local mediators, such as nitric oxide and
endothelin, that cause relaxation or vascular contraction, re-
spectively. Taken together, all these factors make blood pres-
sure changes a complex mechanism [113].
Regarding the association between T and blood pressure,
Zitzmann and Nieschlag, in 2007, demonstrated beneficial
effects of T in the diastolic and systolic blood pressure as well
as resting heart rate, which decreased significantly during
treatment with T in hypogonadal men [114, 115]. Later, other
authors studied the association between the increase or defi-
ciency of androgens with gestational hypertension and pre-
eclampsia. A positive correlation between the increase of an-
drogen levels and preeclampsia was observed [116–118]. It
was also demonstrated that the placental aromatase enzyme,
that is responsible for the conversion of androgens to
oestrogen, is deficient in placental ischemia and preeclamptic
pregnancy [8, 119]. On the other hand, other epidemiological
studies have shown that maternal serum levels of androgens,
such as dehydroepiandrosterone (DHEA), DHEA sulphate,
androstenedione, and T, are elevated in healthy pregnant
women [120, 121]. In accordance, other studies have shown
that T and its 5-reduced metabolites (5α- and 5β-DHT) pro-
duced a marked reduction in the blood pressure of hyperten-
sive and normotensive rats [122]. Particularly, 5β-DHT led to
a substantial acute antihypertensive effect in hypertensive rats
[123], which may be mainly due to a blockade of Ca2+ entry
through L-type VOCC [124]. Concerning the hypertensive
disorders of pregnancy, Perusquia et al. (2018) demonstrated,
for the first time in a rat model of preeclampsia, that andro-
gens, mainly DHEA and 5β-DHT, attenuate hypertension
in vivo due to their vasorelaxant effect, and this is a non-
genomic mediated response [125]. In conclusion, an excess
or insufficient androgen production during pregnancy may
trigger the development of preeclampsia or gestational hyper-
tension. Thus, these studies point out that the administration of
androgens in women with hypertensive disorders of pregnan-
cy is a near possibility. Nevertheless, further clinical studies
are needed.
Testosterone and Heart Diseases
As described above, low levels of T appear to be harmful to
the cardiovascular system due to the observed increase of
CVD risk factors [45, 126]. T not only influences vascular
reactivity but affects peripheral resistance, cardiac electro-
physiology and cardiac output [126]. It is not clear how T
influences ventricular repolarization mechanisms, but it ap-
pears to act by activating K+ channels and simultaneously
reducing the activity of L-type Ca2+ channels, thereby
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increasing the repolarization reserve [69]. Decreased T is also
associated with heart diseases such as coronary artery disease
(CAD), heart failure (HF), ischaemic stroke, and atrial fibril-
lation (AF) [127].
Regarding CAD, some studies have shown an inverse as-
sociation between T levels and CAD. Phillips et al. (1983)
were the first authors to demonstrate that exists an inverse
relationship between free T levels and CAD degree [128].
Similar results were later obtained by Zhao et al. (1998)
[129]. In 2000, English et al. (2000) demonstrated that men
have lower levels of T than men with normal coronary angio-
grams. Interestingly, the authors also found low levels of 17ß-
estradiol, which is suggestive of a direct action of T on the
CAD pathogenesis [43]. Several investigations also evaluated
the carotid artery by ultrasonography and demonstrated that
low T levels were associated with carotid IMT [89, 93, 130,
131], total carotid plaque area [132], and intermittent claudi-
cation [133]. Rosano et al. (2007) in their investigations also
demonstrated that low T levels and 17β-estradiol are associ-
ated with coronary artery disease in male patients with angina.
These results also show that there is an inverse relationship
between the degree of CAD and plasma T levels suggesting
that low plasma T may be involved with the increased risk of
CAD in men [134]. The clinical relevance of low oestradiol
levels after normalization of T levels needs further investiga-
tion as both sex hormones are tightly linked.
Concerning HF, this heart disease is usually associatedwith
an increase in peripheral vasoconstriction [126]. The most
common cause of HF and impaired left ventricular dysfunc-
tion is coronary artery disease (CAD) with resulting cardiac
ischemia, leading to decreased contractility and weakness of
the heart muscle. It is common for men with HF to have low T
levels and this leads to increased mortality [135] as they are
associated with reduced heart function, loss of lean muscle
mass and strength, chronic anaemia and insulin resistance
[126]. Some studies have suggested that there also appears
to be an inverse relationship between total and T-free levels
and HF grade [69], in which case the prevalence of
hypogonadism is greater than 40% [136]. It has been specu-
lated that low T levels may be linked to an anabolic/catabolic
imbalance, a typical feature of advanced HF. Some research
supports this hypothesis as they report that low T levels are
associated with some clinical features of advanced HF (e.g.
reduction of muscle mass, decreased exercise capacity, energy
handling, fatigue dyspnoea, and final cachexia) [136]. Patients
with HF have decreased exercise capacity and muscle fatigue,
but this is not necessarily related to the myocardial dysfunc-
tion degree [136], a fact that is supported by other investiga-
tions [137, 138]. Studies by Jankowska et al. (2006) demon-
strated that low T levels independently predisposed to im-
paired exercise capacity, whereas other indices related to the
heart disease progression were not [137]. Moreover, Srinivas-
Shankar et al. (2010) also reported that age-related decline in
T contributes to a gradually impaired exercise capacity in
older men, and T treatment for 6 months has been shown to
prevent age-associated loss of lower limb muscle strength and
improve body composition, quality of life, and physical func-
tion [138].
Some authors also tried to understand the role of T
on stroke or myocardial infarction. Total production of
T and free T levels appears to be significantly inversely
associated with a higher incidence or severity of a
stroke or transient ischemic attack (TIA), to the 6-
month mortality and the infarct size [127, 139].
Differences between patients and control subjects in se-
rum 17 β-estradiol levels were not found suggesting
that T may directly affect the ischemic stroke pathogen-
esis in men [139]. Mäkinen et al. (2005) also observed
that there is a positive correlation between testosterone
deficiency and increased carotid IMT. Thus, these au-
thors also suggested a possible protective role of T for
the development of atherosclerosis in middle-aged men
[92]. In the same sense, Yeap et al. (2009) also evi-
denced that, in older men, lower T levels predict inci-
dent stroke and TIA, after adjusting for conventional
risk factors for CVD [140]. This can have as several
consequences, such as an increase in carotid IMT, the
formation of an abdominal aortic aneurysm or even the
appearance of lone atrial fibrillation (AF), as demon-
strated later by the same authors [141]. Older men with
abdominal aortic aneurysm have reduced low free T
levels, suggesting that an impaired gonadal function
may be also involved in arterial dilatation as well as
occlusive vascular disease in older men [141].
Recent evidence confirms that low T levels are a risk
factor not only for ischemic stroke but also for AF [142,
143]. An independent association between lone AF and
low levels of T was reported [144], suggesting that T
may be protective for the regulation of myocardial elec-
trical conduction. In the same sense, Zhang et al.(2017)
demonstrated, in castrated mice, that T deficiency is re-
sponsible for the late Na+ current increase, which pro-
logues the action potential repolarization and consequent-
ly, promote an increased susceptibility to AF [145]. Even
if most studies point to an association of low T levels with
an increased risk of developing AF, it has been also
shown that low levels of oestradiol [142] and DHT
[146] may increase the risk of incident AF. Moreover,
some studies have shown that elevated T levels may also
be predictive of AF [147, 148]. More studies are neces-
sary to understand these contradictory data.
Taken together, these studies demonstrated that T
seems to be protective for the development of heart
diseases suggesting, therefore, that low levels of this
sex hormone are a good marker for heart disease’s
diagnosis.
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Potential Therapeutic Application
of Testosterone
TRT may be a therapeutic reality for some of these cardiovas-
cular events [149]. However, currently, T administration has
only been approved by the Food and Drug Administration
(FDA) as replacement therapy in men with low testosterone
levels and with symptoms of hypogonadism, primary
(testicular) or secondary (pituitary-hypothalamic). These
symptoms include decreased spontaneous erections, de-
creased nocturnal penile tumescence decreased libido, de-
creased beard growth and shrinking testicles [150]. On the
other hand, recent findings have shown that TRTmay increase
the incidence of adverse cardiovascular events, although this
issue is still very controversial [46–48].
As previously described, the prescription of TRT to correct
low T levels were associated with a decrease in the incidence
of CVD risk factors [45]. A reduction in the mortality rate of
men with T2DM and hypogonadism was also demonstrated.
As reported in the previous topics, TRT improves fasting
blood glucose, glycated haemoglobin, cholesterol levels, and
obesity in men with hypogonadism [61]. Moreover, they have
shown that TRT improves central obesity and metabolic con-
trol, as well as fat mass in these patients, reduced waist cir-
cumference, insulin resistance, BMI and increased HDL
levels [53, 54, 69]. Other authors have also suggested that
TRT may improve glycaemic control and decrease T2DM
triglyceride levels in men with hypogonadism [61].
However, the mechanism behind the T/obesity/CVD relation-
ship is very complex and to date little is known [82]. TRTalso
decelerates the progression of atherosclerosis and protects
from its clinical sequelae [92], inducing a more favourable
the lipid profile [111, 112]. Interestingly, recent studies found
that TRT increases the volume of uncalcified coronary artery
plaque [151, 152], although it was not associated with more
CV adverse effects in the same investigation. The authors
reported that further studies are needed to prove whether T
increases CV risk. Overall, these studies seem to suggest that
normal T levels are an anti-atherosclerotic pattern. Regarding
dyslipidaemia—the main cause of atherosclerosis—some
studies have also shown the role of T in this disorder. TRT
appears to improve lipid profile, contributing to a decrease in
this CVD risk factor, having, therefore, a protective role on
atherosclerosis [111, 112]. TRT has recently been shown to
decrease cholesterol and insulin levels but was not associated
with markers of glucose and inflammation, fibrinolysis or tro-
ponin. However, the authors noted that the clinical importance
of their study was unclear and further clinical studies should
be performed [153]. Concerning the blood pressure changes,
some studies in men with hypogonadism have also shown that
T has beneficial effects on diastolic and systolic blood pres-
sure as well as resting heart rate [114, 115]. Concerning the
hypertensive disorders during pregnancy, it appears that T
plays an important role in the pathogenesis of preeclampsia,
[154]. An excess or insufficient androgen production during
pregnancy may trigger the development of preeclampsia or
gestational hypertension [125]. Thus, the scientific communi-
ty believes that the administration of androgens in hyperten-
sive disorders of pregnancy is a possibility, however, more
clinical studies are needed.
Concerning the therapeutic application of TRT in men with
symptoms of hypogonadism, several authors also tried to un-
derstand the association between hypogonadism with CVD,
particularly heart failure (HF), angina or myocardial ischemia/
reperfusion [155]. Baillargeon et al. (2014) demonstrated that
TRT did not increase the risk of myocardial infarction com-
pared with a group without TRT [156]. Other authors have
also observed that low T levels are associated with coronary
heart disease [129], and men with proven coronary atheroscle-
rosis had low endogenous androgen levels [157]. Low and
high plasma levels of this hormone have also been associated
with ischemic arterial disease in elderly men [158]. Moreover,
Muraleedharan et al. (2013) suggested that low T levels may
predict increased all-cause mortality [159].
Concerning HF, TRT appears to increase the peak oxygen
consumption (VO2) on exercise testing [160], whereas intra-
venous T administration can increase cardiac output and re-
duce peripheral vascular resistance [161]. The long-term
(chronic) treatment has also been shown to improve some
immunological parameters (TNF-α and IL-1β) which may
lead to a reduction in left ventricular muscle fibrosis [162].
Regarding ischemia/myocardial reperfusion, T has been
shown to relax coronary arteries [126, 135, 163] and the
long-term treatment may increase the time to develop new
ischemia. Clinical trials suggest that T has short- and long-
term effects on cardiac ischemia, responsible for its non-
genomic and genomic actions, respectively [44, 126, 164]. It
has been suggested that coronary arteries are more sensitive to
T in men with a higher deficiency of this hormone [126, 165].
The molecular mechanisms underlying this situation can be
explained based on the non-genomic actions of T [44, 126,
164], however, they remain unknown [135] and further stud-
ies are needed to clarify them [135].
With respect to stroke or myocardial infarction, two large
observational studies reported that TRT increased the risk of
these pathologies in men over 75 years [166, 167]. Vigen et al.
(2013) performed a retrospective national cohort study of men
with low T levels who underwent coronary angiography. The
obtained results demonstrated that the use of TRTwas associ-
ated with an increased risk of adverse outcomes (myocardial
infarction or stroke) [166]. Finkle et al. (2014) performed a
cohort study in men with a higher risk of acute non-fatal myo-
cardial infarction. The authors found TRT substantially in-
creased the risk of myocardial infarction in older and younger
men [167]. However, these two studies have been criticized
once the levels of T and the drug administration following T
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treatment have not been in consideration in these studies,
which may antagonize the T effects [168, 169]. On the other
hand, other authors reported a protective role of T in stroke or
myocardial infarction [170, 171]. The mechanisms involved
in this role of T may be associated with the direct effects of
this hormone on myocardial oxygen consumption and mem-
brane repolarization [41, 135, 165]. Moreover, some studies
suggested that T can reduce the size of myocardial infarct, but
this is not consensual. Further studies are needed to unravel
the role of T in anti-ischemic and/or antianginal therapy [135,
155].
In summary, these studies suggest that T plays an important
role in human health, although it is unclear whether its actions
are clinically relevant in terms of protection from CVD or in
the improvement of an established disease [48, 126, 172].
Because there is no scientific evidence to support the correla-
tion of TRTwith CVD risk factors increase [47] since most of
these studies report a beneficial role from this therapy, T ad-
ministration remains a reality [45]. Despite this, the FDA has
already made a warning statement about the possible CVD
risk factors associated with TRT.
Conclusions and Future Directions
Cardiovascular diseases (CVD) are one of the leading causes
of death worldwide. The knowledge about the vascular effects
of testosterone (T) is crucial to understand its clinical implica-
tions and may lead to new therapeutic targets in the future.
Studies performed over the years agree that T is an important
sex hormone that triggers several genomic and non-genomic
pathways, leading to improvements of several cardiovascular
risk factors and quality of life in men, contrary to what had
been suggested at first instance. T presents genomic and non-
genomic actions at the vascular level, and both effects may
overlap, which makes it difficult to define the broad vascular
effects of androgens. However, the key T effect at the vascular
level is the vasorelaxation, a non-genomic action (rapid
effect).
Several studies have established a relationship between
the low levels of T and an increase in the CVD preva-
lence, which seems to be mainly linked to the non-
genomic actions of T, namely vasorelaxation. This effect
involves several mechanisms including the nuclear recep-
tor activation, the influence of vascular endothelium and
the activation or blocking of ion channels. So, the vaso-
dilator mechanisms of T are crucial to understanding the
relationship between the risk factors for CVD and this sex
hormone.
Several clinical and epidemiological studies observed that
men with type 2 diabetes mellitus, obesity, metabolic syn-
drome, atherosclerosis, dyslipidaemia, and higher blood pres-
sure had lower levels of T, suggesting a beneficial role of T on
the cardiovascular system. Therefore, testosterone replace-
ment therapy (TRT) could be a solution to improve these
CVD risk factors. However, this issue has been the subject
of controversy, as recent studies suggest that TRT is associated
with an increase of CVD. Concerning type 2 diabetes mellitus
and metabolic syndrome, most of the studies showed an asso-
ciation with low levels of T and that TRT improves these risk
factors in men with hypogonadism. Regarding atherosclerosis
and dyslipidaemia, low levels of T were also associated with
an improvement of some parameters of these risk factors.
Moreover, TRT seems to induce a more favourable lipid pro-
file, contributing to increased protection for the development
or progression of atherosclerosis. Regarding the association
between T and blood pressure, few studies have been per-
formed, but it seems that T is beneficial to diastolic and sys-
tolic blood pressure as well as the resting heart rate.
Furthermore, excess or insufficient androgen production dur-
ing pregnancy may trigger the development of preeclampsia
or gestational hypertension. These studies also indicate that
the administration of androgens in hypertensive pregnant
women is a near possibility. Nevertheless, further clinical
studies are needed.
In sum, the vascular effects of testosterone have clinical
implications. However, a consensus on the T effects or the
risks associated with TRT on the cardiovascular system needs
to be established. Considering the overlap between both ge-
nomic and non-genomic effects, and even a possible diver-
gence in the effects of both actions, it is evidenced that a better
understanding of the vascular mechanisms of testosterone is
crucial. Only then their clinical implications will be correctly
established and the development of new therapeutic targets for
cardiovascular diseases can be discovered.
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